{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:08:52Z","timestamp":1772222932135,"version":"3.50.1"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,12,1]]},"abstract":"<jats:p>Objective. Anaphylaxis after immunization, although rare, is serious and potentially life-threatening. Understanding risk factors for this reaction is therefore important. Gelatin is added to many vaccines as a heat stabilizer. Japanese researchers have demonstrated a strong association between immediate hypersensitivity reactions to measles, mumps, rubella, varicella, and Japanese encephalitis immunizations and subsequent detection of anti-gelatin immunoglobulin E (IgE) antibodies. They suggested that previous receipt by these patients of diphtheria-tetanus-acellular pertussis vaccines with trace amounts of gelatin was responsible for the sensitization. We aimed to assess whether a similar association exists for vaccinees in the United States who reported anaphylaxis after receipt of measles-mumps-rubella (MMR) or measles vaccines and to review recent trends in reporting of hypersensitivity reactions.<\/jats:p>\n               <jats:p>Methods. We conducted a retrospective case-control study. Cases of anaphylaxis that met a predefined case definition were identified from the US Vaccine Adverse Event Reporting System (VAERS). Mayo Clinic patients who received MMR vaccine uneventfully served as controls. The study subjects were interviewed to obtain the history of allergies. Sera from study subjects and their matched controls were tested for IgE antibodies to gelatin, whole egg, and vaccine viral antigens using solid-phase radioimmunoassay. Data from the Biologics Surveillance System on annual numbers of doses of MMR and varicella vaccines distributed in the United States were used to evaluate possible changes in reporting of selected allergic adverse events.<\/jats:p>\n               <jats:p>Results. Fifty-seven study subjects were recruited into the study and interviewed. Of these, 22 provided serum samples for IgE testing. Twenty-seven subjects served as a comparison group and provided a sample for IgE testing; 21 of these completed an allergy history questionnaire. Self-reported history of food allergies was present more frequently in the interviewed study subjects than in the controls, whereas the proportions of people with other characteristics were similar in both groups. None of the interviewed people had a history of food allergy to gelatin. The level of anti-gelatin IgE antibodies was significantly higher among study subjects than among controls, whereas the levels of IgE antibodies against egg and all 3 viral antigens did not differ significantly. Of 22 study subjects, 6 (27%) tested positive for anti-gelatin IgE, whereas none of the 27 controls did. The rate of anaphylactic reactions reported to VAERS after measles virus-containing immunization in the United States between 1991 and 1997 is 1.8 per 1 million doses distributed. No substantial increase in the number of reported allergic events after frequently used gelatin containing MMR and varicella vaccines could be observed during the first 4 years (1997\u20132000) since the introduction of diphtheria-tetanus-acellular pertussis vaccines for use in infancy.<\/jats:p>\n               <jats:p>Conclusion. Anaphylactic reactions to MMR in the United States are rare. The reporting rate has the same order of magnitude as estimates from other countries. Almost one fourth of patients with reported anaphylaxis after MMR seem to have hypersensitivity to gelatin in the vaccine. They may be at higher risk of developing anaphylaxis to subsequent doses of other gelatin-containing vaccines. These people should seek an allergy evaluation before such immunization.<\/jats:p>","DOI":"10.1542\/peds.110.6.e71","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"e71-e71","source":"Crossref","is-referenced-by-count":101,"title":["Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States"],"prefix":"10.1542","volume":"110","author":[{"given":"Vitali","family":"Pool","sequence":"first","affiliation":[{"name":"Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Miles","family":"Braun","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kelso","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Allergy Division), Naval Medical Center, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Mootrey","sequence":"additional","affiliation":[{"name":"Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[{"name":"Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Yunginger","sequence":"additional","affiliation":[{"name":"Allergic Diseases Research Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Gargiullo","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the VAERS Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2002,12,1]]},"reference":[{"key":"2021121006392236200_R1","unstructured":"Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse Events Associated With Childhood Vaccines: Evidence Bearing on Causality. Washington, DC: National Academy Press; 1994"},{"key":"2021121006392236200_R2","doi-asserted-by":"crossref","unstructured":"O\u2019Brien TC, Maloney CJ, Tauraso NM. Quantitation of residual host protein in chicken embryo-derived vaccines by radial immunodiffusion. Appl Microbiol.1971;21:780\u2013782","DOI":"10.1128\/am.21.4.780-782.1971"},{"key":"2021121006392236200_R3","doi-asserted-by":"crossref","unstructured":"James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med.1995;332:1262\u20131266","DOI":"10.1056\/NEJM199505113321904"},{"key":"2021121006392236200_R4","doi-asserted-by":"crossref","unstructured":"Baxter DN. Measles immunization in children with a history of egg allergy. Vaccine.1996;14:131\u2013134","DOI":"10.1016\/0264-410X(95)00154-S"},{"key":"2021121006392236200_R5","doi-asserted-by":"crossref","unstructured":"James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr.1998;133:624\u2013628","DOI":"10.1016\/S0022-3476(98)70101-5"},{"key":"2021121006392236200_R6","doi-asserted-by":"crossref","unstructured":"Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol.1993;91:867\u2013872","DOI":"10.1016\/0091-6749(93)90344-F"},{"key":"2021121006392236200_R7","doi-asserted-by":"crossref","unstructured":"Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol.1995;96:563\u2013565","DOI":"10.1016\/S0091-6749(95)70304-7"},{"key":"2021121006392236200_R8","doi-asserted-by":"crossref","unstructured":"Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol.1996;98:1058\u20131061","DOI":"10.1016\/S0091-6749(96)80191-6"},{"key":"2021121006392236200_R9","doi-asserted-by":"crossref","unstructured":"Sakaguchi M, Yamanaka T, Ikeda K, et al. IgE-mediated systemic reactions to gelatin included in the varicella vaccine. J Allergy Clin Immunol.1997;99:263\u2013264","DOI":"10.1016\/S0091-6749(97)70108-8"},{"key":"2021121006392236200_R10","doi-asserted-by":"crossref","unstructured":"Sakaguchi M, Inouye S. Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines. Vaccine.1998;16:68\u201369","DOI":"10.1016\/S0264-410X(97)00152-7"},{"key":"2021121006392236200_R11","doi-asserted-by":"crossref","unstructured":"Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol.1999;103:321\u2013325","DOI":"10.1016\/S0091-6749(99)70508-7"},{"key":"2021121006392236200_R12","doi-asserted-by":"crossref","unstructured":"Singer S, Johnson CE, Mohr R, Holowecky C. Urticaria following varicella vaccine associated with gelatin allergy. Vaccine.1999;17:327\u2013329","DOI":"10.1016\/S0264-410X(98)00209-6"},{"key":"2021121006392236200_R13","doi-asserted-by":"crossref","unstructured":"Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine.1994;12:542\u2013550","DOI":"10.1016\/0264-410X(94)90315-8"},{"key":"2021121006392236200_R14","doi-asserted-by":"crossref","unstructured":"Braun MM, Ellenberg SS. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991\u20131994. J Pediatr.1997;131:529\u2013535","DOI":"10.1016\/S0022-3476(97)70056-8"},{"key":"2021121006392236200_R15","doi-asserted-by":"crossref","unstructured":"Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine.1999;17:2908\u20132917","DOI":"10.1016\/S0264-410X(99)00132-2"},{"key":"2021121006392236200_R16","unstructured":"\u201cCOSTART\u201d Coding Symbols for Thesaurus of Adverse Reaction Terms. Rockville, MD: Public Health Service, Food and Drug Administration; 1995"},{"key":"2021121006392236200_R17","unstructured":"Yunginger JW, Swanson MC. Quantitation and standardization of allergens. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology. 5th ed. Washington, DC: American Society for Microbiology; 1997:868\u2013874"},{"key":"2021121006392236200_R18","unstructured":"SAS\/STAT Software. Procedures Manual, General Linear Model procedure (GLM). Cary, NC: SAS Institute Inc; 1996"},{"key":"2021121006392236200_R19","doi-asserted-by":"crossref","unstructured":"Rietschel RL, Bernier R. Neomycin sensitivity and the MMR vaccine. JAMA.1981;245:571","DOI":"10.1001\/jama.1981.03310310017008"},{"key":"2021121006392236200_R20","doi-asserted-by":"crossref","unstructured":"Elliman D, Dhanraj B. Safe MMR vaccination despite neomycin allergy. Lancet.1991;337:365","DOI":"10.1016\/0140-6736(91)90995-2"},{"key":"2021121006392236200_R21","doi-asserted-by":"crossref","unstructured":"Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy. Am J Dis Child.1993;147:128\u2013129","DOI":"10.1001\/archpedi.1993.02160260018005"},{"key":"2021121006392236200_R22","doi-asserted-by":"crossref","unstructured":"Lear JT, English JS. Anaphylaxis after hepatitis B vaccination. Lancet.1995;345:1249","DOI":"10.1016\/S0140-6736(95)92039-0"},{"key":"2021121006392236200_R23","doi-asserted-by":"crossref","unstructured":"Patja A, Ma\u0308kinen-Kiljunen S, Davidkin I, Paunio M, Peltola H. Allergic reactions to measles-mumps-rubella vaccination. Pediatrics.2001;107(2). Available at: www.pediatrics.org\/cgi\/content\/full\/107\/2\/e27","DOI":"10.1542\/peds.107.2.e27"},{"key":"2021121006392236200_R24","doi-asserted-by":"crossref","unstructured":"Sakaguchi M, Nakayama T, Fujita H, Toda M, Inouye S. Minimum estimated incidence in Japan of anaphylaxis to live virus vaccines including gelatin. Vaccine.2000;19:431\u2013436","DOI":"10.1016\/S0264-410X(00)00206-1"},{"key":"2021121006392236200_R25","doi-asserted-by":"crossref","unstructured":"Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol.2000;106:591\u2013592","DOI":"10.1067\/mai.2000.108433"},{"key":"2021121006392236200_R26","doi-asserted-by":"crossref","unstructured":"Kumagai T, Ozaki T, Kamada M, et al. Gelatin-containing diphtheria-tetanus-pertussis (DTP) vaccine causes sensitization to gelatin in the recipients. Vaccine.2000;18:1555\u20131561","DOI":"10.1016\/S0264-410X(99)00441-7"},{"key":"2021121006392236200_R27","doi-asserted-by":"crossref","unstructured":"Kumagai T, Yamanaka T, Wataya Y, et al. A strong association between HLA-DR9 and gelatin allergy in the Japanese population. Vaccine.2001;19:3273\u20133276","DOI":"10.1016\/S0264-410X(00)00555-7"},{"key":"2021121006392236200_R28","unstructured":"D\u2019Souza RM, Campbell-Lloyd S, Isaacs D, et al. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. Commun Dis Intell.2000;24:27\u201333"},{"key":"2021121006392236200_R29","doi-asserted-by":"crossref","unstructured":"Takahashi H, Pool V, Tsail TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS working group. Vaccine.2000;18:2963\u20132969","DOI":"10.1016\/S0264-410X(00)00111-0"},{"key":"2021121006392236200_R30","doi-asserted-by":"crossref","unstructured":"Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health.1995;85:1706\u20131709","DOI":"10.2105\/AJPH.85.12.1706"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/6\/e71\/1116913\/pe12020000l1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/6\/e71\/1116913\/pe12020000l1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T15:21:22Z","timestamp":1639149682000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/110\/6\/e71\/64518\/Prevalence-of-Anti-Gelatin-IgE-Antibodies-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,1]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2002,12,1]]},"published-print":{"date-parts":[[2002,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.110.6.e71","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12,1]]}}}